366 related articles for article (PubMed ID: 19924695)
41. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
[TBL] [Abstract][Full Text] [Related]
42. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition.
Miwa H; Kubo T; Suzuki A; Nishi K; Kondo T
Neurosci Lett; 2005 May 20-27; 380(1-2):93-8. PubMed ID: 15854758
[TBL] [Abstract][Full Text] [Related]
43. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
[TBL] [Abstract][Full Text] [Related]
44. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions.
Sawada H; Kohno R; Kihara T; Izumi Y; Sakka N; Ibi M; Nakanishi M; Nakamizo T; Yamakawa K; Shibasaki H; Yamamoto N; Akaike A; Inden M; Kitamura Y; Taniguchi T; Shimohama S
J Biol Chem; 2004 Mar; 279(11):10710-9. PubMed ID: 14672949
[TBL] [Abstract][Full Text] [Related]
45. N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse.
Berman AE; Chan WY; Brennan AM; Reyes RC; Adler BL; Suh SW; Kauppinen TM; Edling Y; Swanson RA
Ann Neurol; 2011 Mar; 69(3):509-20. PubMed ID: 21446024
[TBL] [Abstract][Full Text] [Related]
46. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.
Elkon H; Melamed E; Offen D
Cell Mol Neurobiol; 2001 Dec; 21(6):771-81. PubMed ID: 12043847
[TBL] [Abstract][Full Text] [Related]
47. Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.
Baydyuk M; Nguyen MT; Xu B
Exp Neurol; 2011 Mar; 228(1):118-25. PubMed ID: 21192928
[TBL] [Abstract][Full Text] [Related]
48. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
Sulzer D
Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
[TBL] [Abstract][Full Text] [Related]
49. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
Zhang X; Xie W; Qu S; Pan T; Wang X; Le W
Biochem Biophys Res Commun; 2005 Jul; 333(2):544-9. PubMed ID: 15950935
[TBL] [Abstract][Full Text] [Related]
50. Measurement of proteasomal dysfunction in cell models of dopaminergic degeneration.
Sun F; Kanthasamy AG; Kanthasamy A
Methods Mol Biol; 2011; 758():293-305. PubMed ID: 21815074
[TBL] [Abstract][Full Text] [Related]
51. [EFFECT OF QUERCETIN ON NEURODEGENERATIVE AND COMPENSATORY PROCESSES IN NIGROSTRIATAL SYSTEM IN A MODEL OF PRECLINICAL PARKINSON''S DISEASE STAGE IN RATS].
Ekimova IV; Plaksina DV
Ross Fiziol Zh Im I M Sechenova; 2016 Jun; 102(6):647-58. PubMed ID: 30192489
[TBL] [Abstract][Full Text] [Related]
52. Degeneration of mesencephalic dopaminergic neurons in klotho mouse related to vitamin D exposure.
Kosakai A; Ito D; Nihei Y; Yamashita S; Okada Y; Takahashi K; Suzuki N
Brain Res; 2011 Mar; 1382():109-17. PubMed ID: 21276773
[TBL] [Abstract][Full Text] [Related]
53. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
54. Proteasome inhibition in medaka brain induces the features of Parkinson's disease.
Matsui H; Ito H; Taniguchi Y; Inoue H; Takeda S; Takahashi R
J Neurochem; 2010 Oct; 115(1):178-87. PubMed ID: 20649841
[TBL] [Abstract][Full Text] [Related]
55. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.
Grünblatt E; Ruder J; Monoranu CM; Riederer P; Youdim MB; Mandel SA
Neurotox Res; 2018 Apr; 33(3):560-568. PubMed ID: 29218503
[TBL] [Abstract][Full Text] [Related]
56. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats.
Inden M; Kondo J; Kitamura Y; Takata K; Nishimura K; Taniguchi T; Sawada H; Shimohama S
J Pharmacol Sci; 2005 Feb; 97(2):203-11. PubMed ID: 15684568
[TBL] [Abstract][Full Text] [Related]
57. Are ubiquitination pathways central to Parkinson's disease?
Giasson BI; Lee VM
Cell; 2003 Jul; 114(1):1-8. PubMed ID: 12859888
[TBL] [Abstract][Full Text] [Related]
58. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.
Klein RL; Dayton RD; Henderson KM; Petrucelli L
Neurosci Lett; 2006 Jun; 401(1-2):130-5. PubMed ID: 16554120
[TBL] [Abstract][Full Text] [Related]
59. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway.
Lang-Rollin I; Vekrellis K; Wang Q; Rideout HJ; Stefanis L
J Neurochem; 2004 Sep; 90(6):1511-20. PubMed ID: 15341534
[TBL] [Abstract][Full Text] [Related]
60. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
